Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Genprex.

    Client Virtual Booth

    GENPREX

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Genprex
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Dell Medical Center Health Discovery Building 1601 Trinity Street, Bldg B Suite 3.322 Austin, TX 78712-1885
    Telephone
    Telephone
    (877) 774-GNPX (4679)
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.genprex.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/genprex
    Twitter
    Twitter
    https://twitter.com/genprex

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

    Details:

    NPRL2 gene therapy induces effective anti-tumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model.


    Lead Product(s): NPRL2 Gene Therapy

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 02, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Genprex Inc. Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC

    Details:

    Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX nanoparticle delivery system and combination with Tecentriq for the treatment of small cell lung cancer.


    Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab

    Therapeutic Area: Oncology Product Name: Reqorsa

    Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 21, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer

    Details:

    Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX nanoparticle delivery system and combination with Tecentriq in extensive-stage small cell lung cancer.


    Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab

    Therapeutic Area: Oncology Product Name: Reqorsa

    Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 10, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh

    Details:

    Under the agreement, Genprex gains a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to a gene therapy, GPX-002, for both Type 1 and Type 2 diabetes.


    Lead Product(s): GPX-002

    Therapeutic Area: Endocrinology Product Name: GPX-002

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Recipient: The University of Pittsburgh School of Medicine

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement July 18, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

    Details:

    Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX nanoparticle delivery system and combination with Tagrisso in advanced non-small cell lung cancer.


    Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab

    Therapeutic Area: Oncology Product Name: Reqorsa

    Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 11, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cance...

    Details:

    Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) uses Genprex’s unique, proprietary ONCOPREX Nanoparticle Delivery System and Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer


    Lead Product(s): Quaratusugene Ozeplasmid,Atezolizumab

    Therapeutic Area: Oncology Product Name: Reqorsa

    Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 28, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA in Combination with Tag...

    Details:

    Reqorsa Immunogene Therapy (quaratusugene ozeplasmid)uses Genprex’s unique, proprietary ONCOPREX® Nanoparticle Delivery System Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer


    Lead Product(s): Quaratusugene Ozeplasmid,Osimertinib Mesylate

    Therapeutic Area: Oncology Product Name: Reqorsa

    Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 30, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh

    Details:

    University of Pittsburgh grants Genprex a preclinical technology that transforms macrophages, complementary to the GPX-002 diabetes technology. Novel infusion process uses an endoscope and an AAV vector with a glucagon promoter to deliver the Pdx1 + MafA genes to the pancreas.


    Lead Product(s): GPX-002

    Therapeutic Area: Endocrinology Product Name: GPX-002

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: The University of Pittsburgh School of Medicine

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement January 05, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabete...

    Details:

    The diabetes gene therapy, GPX-002, is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas.


    Lead Product(s): GPX-002

    Therapeutic Area: Endocrinology Product Name: GPX-002

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: University of Pittsburgh

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 04, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh

    Details:

    Diabetic mice studies have shown that GPX-002, a gene therapy for diabetes, restored normal blood glucose levels for an extended period of time, which could translate to decades in humans.


    Lead Product(s): GPX-002

    Therapeutic Area: Endocrinology Product Name: GPX-002

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Recipient: The University of Pittsburgh School of Medicine

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement December 15, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search